Welcure Drugs and Pharmaceuticals Ltd has signed Letter of Intent (LOI) with Singapore's Telexcell Trade PTE Ltd for a strategic equity investment. Telexcell plans to acquire up to 25% stake in Welcure at an indicative price of ₹20 per share, a significant premium. This all-cash deal, pending due diligence and regulatory approvals, is set to strengthen Welcure's global market position.